Anees B. Chagpar MD, MSc, MA, MPH, MBA, FRCS(C), FACS
Associate Professor of Surgery (Oncology); Director, The Breast Center at Smilow Cancer Hospital at Yale-New Haven; Program Director, Interdisciplinary Breast Fellowship; Assistant Director, Diversity and Health Equity at Yale Cancer Center
Large Database/Outcomes Research:
We use a series of large databases including the National Health Interview Survey, the National Cancer Database, and in house surveys to answer important clinical and outcomes questions. In particular, we have been interested in clinical prediction modelling, diversity and health equity issues, cancer screening and survivorship issues, and cost, quality and access to care.
Prospective Therapeutic Clinical Trials:
SHAVE: A randomized controlled trial of routine shave margins vs. standard partial mastectomy
A Chemoprevention Study of Black Cohosh in Women with DCIS
PREHAB: A randomized pre-surgical window trial of mindfulness vs. exercise on biomarkers in breast cancer patients
Collaborative Translational Research:
Understanding the intersection between clinical phenotype and intratumoral heterogeneity using whole genome next-generation sequencing (with Lajos Pusztai, MD, DPhil)
Modelling Human Immune System Interaction with Breast Tumors and Treatments in Mice (with Alfred Bothwell, PhD and Joanne Sweasy, PhD)
Capsacin and eosin in local therapy for breast cancer (with John Giebel, PhD)
Extensive Research Description
My research has focused on breast cancer and while it spans the spectrum of inquiry related to this disease process, the majority of it falls into several large themes:
Chest Wall Recurrence: I began to become very interested in chest wall recurrences (CWR) after mastectomy and did a number of studies in this area. Several findings were key and were significant contributions to the literature and in fact were practice changing.
(i) Prognosis: While it had previously been thought that all patients with CWR had a dismal prognosis, I was able to define a group in whom prognosis was not poor, and in whom aggressive management was warranted. I developed a clinical prediction model to assess prognosis in these patients. This is now widely used, and was quoted by every speaker in a plenary session at the American College of Surgeons on the management of CWR.
(ii) Reconstruction: I was able to demonstrate that patients who develop a CWR after having had breast reconstruction did not need to have their reconstruction taken down. This finding which allowed many women to maintain their reconstruction despite having a CWR won the best poster award at the Southwestern Surgical Congress.
(iii)Radiation: I defined not only the need for radiation therapy after CWR, but also added to the literature findings to support the use of post-mastectomy radiation therapy, which has now become widely accepted and supported by ASCO and ASTRO guidelines.
Sentinel Lymph Node Biopsy: Much of my work has focused on various issues surrounding sentinel lymph node biopsy (SLNB) in the management of breast cancer patients. I validated the subareolar injection technique in the world’s largest series (4131 patients); this is now considered by many to be the optimal injection technique for SLNB. I elucidated, in one of the most widely quoted studies, the association between immunohistochemically detected sentinel node deposits and prognosis, a study which won me an ASCO Merit Award. I identified factors associated with a failure to identify a sentinel lymph node, which has encouraged surgeons to use dual tracer technique to optimize identification rates. I explored the use of lymphoscintigraphy and the finding of internal mammary nodes (IMN), finding that positive IMN nodes frequently do not change prognosis or management – this is one of the oft-quoted studies for why many surgeons do not routinely use lymphoscintigraphy or do IMN biopsies. I published that there was no difference in SLN-positivity rates based on biopsy type – a study that contradicted the myth that core needle biopsy could spread cancer cells into lymph nodes. This was important as excisional biopsy is now considered suboptimal, and needle biopsies are favored. Having an extensive background in SLNB, I acquired skills in clinical prediction modeling through my MPH at Harvard, and created a number of clinical prediction rules which have now been validated in a number of studies. I consider these seminal contributions to the literature, as these prediction rules allow for the prediction of (i) non-sentinel node metastases in SLN-positive patients using preoperative and intraoperative factors alone, (ii) the finding of four or more positive SLNs in patients with tumors < 5 cm and 1-3 positive SLNs, as these patients are at risk of requiring post-mastectomy radiation therapy and this prediction model (which again is based on preoperative and intraoperative factors) may alter decision-making for immediate breast reconstruction, and (iii) the finding of any positive node in a cohort of elderly patients as these are patients in whom comorbidities may cause risks to outweigh benefits of SLNB if the risk of a positive node is low. Previous prediction models of non-sentinel node metastases had always used postoperative final pathologic data, which did not aid intraoperative decision-making. Our models, however, relied only on data available to the surgeon at this time point, and formed the basis of an NIH grant which was designed to strengthen these models using intraoperative RT-PCR based data.
Mammography and Screening in Population-Based Studies: I have worked extensively with the National Health Interview Survey to understand trends in mammography and screening in the US population. I was one of the first to demonstrate that the recent decline in breast cancer incidence rates was not due solely to a reduction in hormone replacement therapy use, but also to a decline in mammography screening. I defined the use of mammography in various racial cohorts, and analyzed mammography usage based on risk stratifications. This work was cited by the US Preventative Services Task Force in their review of significant literature in their recent 2010 position statement regarding screening mammography. ·
Other: I have been interested in a potpourri of other studies, from identifying biomarkers in nipple aspirate fluid, to understanding the prognostic significance of concomitant DCIS in patients with invasive cancer (a study which won the best paper award at the Central Surgical Association meeting).